Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study-Reference-Cited by-同舟云学术

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study

Published:2017-08-16 Issue:2 Volume:24 Page:211-220
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Liesner R. J.¹,Abashidze M.²,Aleinikova O.³,Altisent C.⁴,Belletrutti M. J.⁵,Borel-Derlon A.⁶,Carcao M.⁷^ORCID,Chambost H.⁸,Chan A. K. C.⁹,Dubey L.¹⁰,Ducore J.¹¹,Fouzia N. A.¹²,Gattens M.¹³,Gruel Y.¹⁴,Guillet B.¹⁵,Kavardakova N.¹⁶,El Khorassani M.¹⁷,Klukowska A.¹⁸,Lambert T.¹⁹,Lohade S.²⁰,Sigaud M.²¹,Turea V.²²,Wu J. K. M.²³,Vdovin V.²⁴,Pavlova A.²⁵,Jansen M.²⁶,Belyanskaya L.²⁷,Walter O.²⁷,Knaub S.²⁷,Neufeld E. J.²⁸

Affiliation:

1. Great Ormond Hospital for Children NHS Trust Haemophilia Centre; London UK

2. JSC Institute of Haematology and Transfusiology; Tbilisi Georgia

3. Republican Scientific and Practical Centre of Children Oncology, Hematology and Immunology; Minsk Belarus

4. Unitat d'Hemofilia; Hospital Vall D'Hebron; Barcelona Spain

5. Pediatric Hematology; Department of Pediatrics; University of Alberta; Edmonton AB Canada

6. Hôpital de la Côte de Nacre; Caen France

7. Hospital for Sick Children; Toronto ON Canada

8. Department of Pediatric Hematology Oncology; Children Hospital La Timone; APHM and Inserm; UMR 1062; Aix Marseille University; Marseille France

9. Division of Pediatric Hematology/Oncology; McMaster University; Hamilton ON Canada

10. Western Ukrainian Specialized Children's Medical Centre; Lviv Ukraine

11. Department of Pediatrics; UC Davis Medical Center; Sacramento CA USA

12. Christian Medical College Vellore; Vellore India

13. Cambridge University Hospital NHS Foundation Trust; Cambridge UK

14. Hôpital Trousseau; Centre Régional de Traitement de l'Hémophilie; Tours France

15. Haemophilia Treatment Centre of Rennes-Brittany; University Hospital of Rennes; Rennes France

16. National Children's Specialized Clinic “OHMATDET”; Kiev Ukraine

17. Centre de traitement de l'hémophilie; University Mohamed V; Rabat Morocco

18. Warsaw Medical University; Warsaw Poland

19. CRTH Hôpital Universitaire Bicêtre APHP; Le Kremlin Bicêtre France

20. Sahyadri Speciality Hospital; Pune India

21. Centre Régional de Traitement de I'Hémophilie; University Hospital of Nantes; Nantes France

22. Scientific Research Institute of Mother and Child Health Care; Chişinău Moldova

23. B.C. Children's Hospital; Vancouver BC Canada

24. Morozovskaya Children's Hospital; Moscow Russia

25. Institute of Experimental Haematology and Transfusion Medicine; University Clinic Bonn; Bonn Germany

26. Octapharma Pharmazeutika Produktionsges.mbH; Vienna Austria

27. Octapharma AG; Lachen Switzerland

28. St. Jude Children’s Research Hospital; Memphis TN USA

Funder

Octapharma AG

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13320/fullpdf

Reference30 articles.

1. Key insights to understand the immunogenicity of FVIII products;Goudemand;Thromb Haemost,2016

2. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity;Oldenburg;Haematologica,2015

3. European Medicines Agency Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins

4. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A;Peyvandi;N Engl J Med,2016

5. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study;Gouw;Blood,2007

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada;Research and Practice in Thrombosis and Haemostasis;2023-11

2. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study;Expert Review of Hematology;2023-09-07

3. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect study;European Journal of Haematology;2023-07-13

4. Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A;Haemophilia;2023-05-30

5. BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial;Thrombosis and Haemostasis;2023-01